Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.
-
Privacy Policy
-
News
- EBOVAC1 consortium reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination - 14th March 2017
EBOVAC1 consortium reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination - 14th March 2017
NEWS
-
The Utility of a Two-Dose Ebola Vaccine Regimen Confirmed
In response to the 2014-2016 Ebola epidemic, the clinical development of a two-dose regimen of...
-
8th EBOVAC2 Newsletter
The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission...
-
European Commission Approval for Janssen’s Ebola vaccine regimen
Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted...
-
Positive CHMP Opinion for Janssen's Ebola Vaccine Regimen
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola...
-
Ebovac2 at ECCMID 2019
An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the...
-
Ebola: background
What is Ebola?
-
Phase 2 trials
Find out more about EBOVAC2 trials
-
Work programme
EBOVAC2 is organised into 6 workpackages (WP)
-
Ebola+ programme
Contributes to efforts to tackle a wide range of challenges in Ebola research
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA